Author:
Kong Yuanfang,Liu Shuanglin,Wang Shaopei,Yang Bin,He Wei,Li Hehe,Yang Siqi,Wang Guoqing,Dong Chunhong
Abstract
AbstractCatalpol, a natural product mainly existed in plenty of Chinese traditional medicines, is an iridoid compound with the comprehensive effects on neuroprotective, anti-inflammatory, choleretic, hypoglycemic and anticancer. However, there are some disadvantages for catalpol such as a short half-life in vivo, low druggability, stingy binding efficiency to target proteins and so on. It is necessary to make structural modification and optimization which enhance its performance on disease treatments and clinic applications. Pyrazole compounds have been reported to have excellent anticancer activities. Based on the previous research foundation of our research group on iridoids and the anticancer activities of catalpol and pyrazole, a series of pyrazole modified catalpol compounds were synthesized by principle of drug combination for serving as potential cancer inhibitors. These derivatives are characterized by 1H NMR, 13C NMR and HRMS. The efficacy of anti-esophageal cancer and anti-pancreatic cancer activities were evaluated by the MTT assay on two esophageal cancer cells Eca-109 and EC-9706, and two pancreatic cancer cells PANC-1, BxPC-3 and normal pancreatic cell line HPDE6-C7, which showed that the compound 3e had strong inhibitory activity against esophageal cancer cells, this providing a theoretical basis for the discovery of catalpol-containing drugs.
Funder
Zhongjing Scholars Research Funding of Henan University of Chinese Medicine
Henan Provincial Science and Technology Research Project
Publisher
Springer Science and Business Media LLC
Reference24 articles.
1. Kamel, M. M. & Megally Abdo, N. Y. Synthesis of novel 1,2,4-triazoles, triazolothiadiazines and triazolothiadiazoles as potential anticancer agents. Eur. J. Med. Chem. 86, 75–80 (2014).
2. Chen, J., Lin, Y., Cai, W., Su, T., Wang, B., Li, J., Wu, J., Pan, J., Chen, C. A new clinical staging system for esophageal cancer to predict survival after definitive chemoradiation or radiotherapy. Dis. Esophagus. 31, 1–9 (2018).
3. Wang, A. H. et al. Epidemiological studies of esophageal cancer in the era of genome-wide association studies. World J. Gastroenterol. 5, 335–343 (2014).
4. Bystricky, B., Okines, A. F. & Cunningham, D. Optimal therapeutic strategies for resectable oesophageal or oesophagogastric junction cancer. Drugs 71, 541–555 (2011).
5. Von Hoff, D. D. et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N. Engl. J. Med. 369, 1691–1703 (2013).
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献